HAVCR2 and acute myeloid leukemia: Specifically, in AML patients who failed combined chemotherapy with the exportin 1 inhibitor, Selinexor, and age-adjusted cytarabine (HiDAC) and mitoxantrone (Mito), Gal-9 and TIM-3 levels were elevated post- versus pre-treatment in bone marrow and blood samples [101].